FMCG Gurus -FMCG Gurus – Eating Better, Not Less – Trend Report – 2026

FMCG Gurus – Eating Better, Not Less – Trend Report – 2026

  • EUR (€)
  • GBP (£)
  • USD ($)

FMCG Gurus – Eating Better, Not Less – Trend Report – 2026

 Geographies: Global  Industries: Health and Well-Being, Trend Reports, Trend Resources, Weight Loss Medication, Weight Management  Published Date: 2026

Buy Now for £1200

FMCG Gurus – Eating Better, Not Less – Trend Report – 2026

Report Description:

As GLP-1 medications reshape the weight-management market, Generation Z is emerging as an important but sensitive audience. Despite being less likely than older consumers to consider themselves overweight, younger adults are more likely to be dieting to lose weight, while appearance, social media, and expectations around physical transformation can influence their attitudes toward weight management.

This report explores why the GLP-1 opportunity should move beyond encouraging consumers to simply eat less and instead focus on helping them eat better. It examines Generation Z’s relationship with GLP-1 medication, nutrient intake, dieting behaviors, appearance, and sources of influence, highlighting the importance of nutrient-dense nutrition, realistic expectations, and responsible positioning. The report provides guidance on how brands can support reduced appetites while promoting adequate protein, fiber, and overall nutritional quality.

The Challenge / Problem for Brands:

Generation Z combines high engagement with GLP-1 medication with greater appearance consciousness and a more restrictive approach to dieting. Reduced appetite could further reinforce behaviors centered around minimizing food and calorie intake rather than improving dietary quality. Brands must therefore capture the GLP-1 opportunity without encouraging excessive restriction, unrealistic expectations, or appearance-led weight loss.

Proposed Solution / Problem It Solves:

Brands should develop GLP-1 support propositions around nutrient density, responsible use, and holistic well-being. Smaller, nutrient-dense formats that maximize nutritional value can help consumers maintain adequate nutrition despite reduced appetites, while credible guidance and realistic messaging can encourage healthier and more sustainable weight-management behaviors.

Risk of Getting This Wrong:

Positioning GLP-1 support primarily around rapid or maximum weight loss risks reinforcing unhealthy attitudes toward food and physical appearance. Overreliance on celebrity influence or messaging centered on restriction could also undermine credibility and create reputational risks as scrutiny of the GLP-1 market grows.

This report helps you decide:

How to develop and position GLP-1 support products for Generation Z, how to maximize nutritional value within smaller eating occasions, and how to communicate around weight management responsibly. It also identifies opportunities to extend nutritional support beyond active medication use and encourage sustainable eating behaviors over the longer term.

Who this is for:

Food, beverage, supplement, and nutrition brands, GLP-1 support product developers, ingredient suppliers, and innovation and marketing teams looking to respond responsibly to the evolving weight-management market.

FMCG Gurus – Eating Better, Not Less – Trend Report – 2026

Report Description:

As GLP-1 medications reshape the weight-management market, Generation Z is emerging as an important but sensitive audience. Despite being less likely than older consumers to consider themselves overweight, younger adults are more likely to be dieting to lose weight, while appearance, social media, and expectations around physical transformation can influence their attitudes toward weight management.

This report explores why the GLP-1 opportunity should move beyond encouraging consumers to simply eat less and instead focus on helping them eat better. It examines Generation Z’s relationship with GLP-1 medication, nutrient intake, dieting behaviors, appearance, and sources of influence, highlighting the importance of nutrient-dense nutrition, realistic expectations, and responsible positioning. The report provides guidance on how brands can support reduced appetites while promoting adequate protein, fiber, and overall nutritional quality.

The Challenge / Problem for Brands:

Generation Z combines high engagement with GLP-1 medication with greater appearance consciousness and a more restrictive approach to dieting. Reduced appetite could further reinforce behaviors centered around minimizing food and calorie intake rather than improving dietary quality. Brands must therefore capture the GLP-1 opportunity without encouraging excessive restriction, unrealistic expectations, or appearance-led weight loss.

Proposed Solution / Problem It Solves:

Brands should develop GLP-1 support propositions around nutrient density, responsible use, and holistic well-being. Smaller, nutrient-dense formats that maximize nutritional value can help consumers maintain adequate nutrition despite reduced appetites, while credible guidance and realistic messaging can encourage healthier and more sustainable weight-management behaviors.

Risk of Getting This Wrong:

Positioning GLP-1 support primarily around rapid or maximum weight loss risks reinforcing unhealthy attitudes toward food and physical appearance. Overreliance on celebrity influence or messaging centered on restriction could also undermine credibility and create reputational risks as scrutiny of the GLP-1 market grows.

This report helps you decide:

How to develop and position GLP-1 support products for Generation Z, how to maximize nutritional value within smaller eating occasions, and how to communicate around weight management responsibly. It also identifies opportunities to extend nutritional support beyond active medication use and encourage sustainable eating behaviors over the longer term.

Who this is for:

Food, beverage, supplement, and nutrition brands, GLP-1 support product developers, ingredient suppliers, and innovation and marketing teams looking to respond responsibly to the evolving weight-management market.

Files included in this report:

  • FMCG-Gurus-Eating-Better-Not-Less-Trend-Report-2026.pdf
  • FMCG-Gurus-Eating-Better-Not-Less-Trend-Report-2026.pptx
  • If you are a user, click here to login and download the report.

Report Agenda and Insights available:

Executive summary
  • [WM184] How would you currently describe your weight? - 2021, 2019, 2018, 2023, 2025
  • [WM922] Are you currently on a diet specifically to lose weight? - 2021, 2019, 2018, 2023, 2025
  • [WLM982] Do you currently use GLP-1 drugs or injections such as Ozempic or Wegovy? - 2025
  • [WM361] What steps have you taken to lose weight? Please select all that apply - 2021, 2019, 2018, 2023, 2025
  • [WLM097] How effective do you feel GLP-1 drugs or injections such as Ozempic or Wegovy have been? - 2025
  • [WM105] How influential are the following sources when it comes to finding out information around trying to lose weight? - 2021, 2019, 2018, 2023, 2025
  • [WLM985] To what extent do you agree with the following statements? Please select all that apply - 2025
  • [WM699] Why do you think a health weight is important? Please select the answer that best fits - 2021, 2019, 2023, 2025
  • [WLM946] Where did you first find out about GLP-1 drugs or injections such as Ozempic or Wegovy. Please select the answer that best fits - 2025
  • [HH910] Overall, what are your biggest health concerns? Please select all that apply - 2025
  • [WLM572] What do you think the biggest challenges are to GLP-1 drugs or injections industry in the long-term? Please select all that apply - 2025
Context & consumer priorities
  • [WM184] How would you currently describe your weight? - 2021, 2019, 2018, 2023, 2025
  • [WM922] Are you currently on a diet specifically to lose weight? - 2021, 2019, 2018, 2023, 2025
  • [HH910] Overall, what are your biggest health concerns? Please select all that apply - 2025
  • [WLM982] Do you currently use GLP-1 drugs or injections such as Ozempic or Wegovy? - 2025
  • [WLM097] How effective do you feel GLP-1 drugs or injections such as Ozempic or Wegovy have been? - 2025
  • [WLM985] To what extent do you agree with the following statements? Please select all that apply - 2025
  • [WLM985] To what extent do you agree with the following statements? Please select all that apply - 2025
  • [WM361] What steps have you taken to lose weight? Please select all that apply - 2021, 2019, 2018, 2023, 2025
  • [WM105] How influential are the following sources when it comes to finding out information around trying to lose weight? - 2021, 2019, 2018, 2023, 2025
  • [WLM946] Where did you first find out about GLP-1 drugs or injections such as Ozempic or Wegovy. Please select the answer that best fits - 2025
  • [WLM572] What do you think the biggest challenges are to GLP-1 drugs or injections industry in the long-term? Please select all that apply - 2025
Case studies
  • [WM699] Why do you think a health weight is important? Please select the answer that best fits - 2021, 2019, 2023, 2025

Files included in this report:

  • FMCG-Gurus-Eating-Better-Not-Less-Trend-Report-2026.pdf
  • FMCG-Gurus-Eating-Better-Not-Less-Trend-Report-2026.pptx
  • If you are a user, click here to login and download the report.